JPH06503098A - ２−デオキシストレプトアミンのタイプの抗生物質の用途 - Google Patents

２−デオキシストレプトアミンのタイプの抗生物質の用途

Info

Publication number: JPH06503098A
Authority: JP; Japan
Prior art keywords: antibiotics; intron; deoxystreptamine; introns; group
Prior art date: 1991-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP5501822A

Other languages

English (en)

Japanese (ja)

Inventor

フォン・アーゼン・ウーヴェ

Original Assignee

エヌ・ゼツト・ワイ・エム・インコーポレイテツド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-09

Filing date

1992-07-08

Publication date

1994-04-07

1992-07-08 Application filed by エヌ・ゼツト・ワイ・エム・インコーポレイテツド filed Critical エヌ・ゼツト・ワイ・エム・インコーポレイテツド

1994-04-07 Publication of JPH06503098A publication Critical patent/JPH06503098A/ja

Status Pending legal-status Critical Current

Links

239000003242 anti bacterial agent Substances 0.000 title claims description 26
229940088710 antibiotic agent Drugs 0.000 title claims description 24
DTFAJAKTSMLKAT-JDCCYXBGSA-N 2-deoxystreptamine Chemical compound N[C@H]1C[C@@H](N)[C@H](O)[C@@H](O)[C@@H]1O DTFAJAKTSMLKAT-JDCCYXBGSA-N 0.000 title claims description 11
108091092195 Intron Proteins 0.000 claims description 19
229930182566 Gentamicin Chemical class 0.000 claims description 4
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical class O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
230000003115 biocidal effect Effects 0.000 claims description 4
229960002518 gentamicin Drugs 0.000 claims description 4
229960000707 tobramycin Drugs 0.000 claims description 4
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 4
229930183998 Lividomycin Natural products 0.000 claims description 2
UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims description 2
229960000318 kanamycin Drugs 0.000 claims description 2
229930027917 kanamycin Natural products 0.000 claims description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
229930182823 kanamycin A Natural products 0.000 claims description 2
229950003076 lividomycin Drugs 0.000 claims description 2
DBLVDAUGBTYDFR-SWMBIRFSSA-N lividomycin A Chemical compound O([C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@H]([C@H]1O)O[C@H]1O[C@H]([C@H]([C@H](O)[C@H]1N)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)CN)[C@H]1O[C@H](CO)[C@@H](O)C[C@H]1N DBLVDAUGBTYDFR-SWMBIRFSSA-N 0.000 claims description 2
229960001914 paromomycin Drugs 0.000 claims description 2
UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 2
229960003704 framycetin Drugs 0.000 claims 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 1
150000002337 glycosamines Chemical class 0.000 claims 1
229960003485 ribostamycin Drugs 0.000 claims 1
229930190553 ribostamycin Natural products 0.000 claims 1
NSKGQURZWSPSBC-NLZFXWNVSA-N ribostamycin Chemical compound N[C@H]1[C@H](O)[C@@H](O)[C@H](CN)O[C@@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](CO)O2)O)[C@H](O)[C@@H](N)C[C@H]1N NSKGQURZWSPSBC-NLZFXWNVSA-N 0.000 claims 1
NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 claims 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 11
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
108700024394 Exon Proteins 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 6
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 6
230000015556 catabolic process Effects 0.000 description 6
229940029575 guanosine Drugs 0.000 description 6
238000000034 method Methods 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
230000007246 mechanism Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
108091026890 Coding region Proteins 0.000 description 3
241000206602 Eukaryota Species 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003292 glue Substances 0.000 description 3
244000052769 pathogen Species 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
108091027874 Group I catalytic intron Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000254 damaging effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000007017 scission Effects 0.000 description 2
229940063673 spermidine Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
XEQLFNPSYWZPOW-NUOYRARPSA-N (2r)-4-amino-n-[(1r,2s,3r,4r,5s)-5-amino-4-[(2r,3r,4r,5s,6r)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-hydroxycyclohexyl]-2-hydroxybutanamide Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)O)NC(=O)[C@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1N XEQLFNPSYWZPOW-NUOYRARPSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
-1 Amine compounds Chemical class 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
229910021620 Indium(III) fluoride Inorganic materials 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
QBWLTQZEVUXXSR-RROBTUQGSA-N Nebramine Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N QBWLTQZEVUXXSR-RROBTUQGSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108020005093 RNA Precursors Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000223892 Tetrahymena Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
210000001557 animal structure Anatomy 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229950004527 butirosin Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
210000002706 plastid Anatomy 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
JNLSTWIBJFIVHZ-UHFFFAOYSA-K trifluoroindigane Chemical compound F[In](F)F JNLSTWIBJFIVHZ-UHFFFAOYSA-K 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP5501822A 1991-07-09 1992-07-08 ２−デオキシストレプトアミンのタイプの抗生物質の用途 Pending JPH06503098A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AT0137591A AT397102B (de)	1991-07-09	1991-07-09	Verwendung eines antibiotikums des typs 2-desoxystreptamin
AT1375/91		1991-07-09
PCT/AT1992/000087 WO1993000907A1 (fr)	1991-07-09	1992-07-08	Utilisation d'un antibiotique du type 2-desoxystreptamine

Publications (1)

Publication Number	Publication Date
JPH06503098A true JPH06503098A (ja)	1994-04-07

Family

ID=3512526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5501822A Pending JPH06503098A (ja)	1991-07-09	1992-07-08	２−デオキシストレプトアミンのタイプの抗生物質の用途

Country Status (7)

Country	Link
EP (1)	EP0548314A1 (fr)
JP (1)	JPH06503098A (fr)
AT (1)	AT397102B (fr)
AU (1)	AU664191B2 (fr)
CA (1)	CA2091264A1 (fr)
FI (1)	FI931018L (fr)
WO (1)	WO1993000907A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08502966A (ja) *	1992-10-23	1996-04-02	ユニバーシティー・オブ・マサチューセッツ・メディカル・センター	Ｒｎａ／リガンド結合の低分子抑制
ES2174957T5 (es) *	1994-07-29	2006-12-16	Innogenetics N.V.	Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
US5433291A (en) *	1994-12-07	1995-07-18	Shoestock, Sr.; Richard F.	Combination tree stand and wheeled game carrier
DE10150783A1 (de) *	2001-10-15	2003-04-24	Bayer Cropscience Ag	Splicing als Target zum Identifizieren neuer Wirkstoffe

1991
- 1991-07-09 AT AT0137591A patent/AT397102B/de not_active IP Right Cessation
1992
- 1992-07-08 JP JP5501822A patent/JPH06503098A/ja active Pending
- 1992-07-08 EP EP92914480A patent/EP0548314A1/fr not_active Ceased
- 1992-07-08 CA CA002091264A patent/CA2091264A1/fr not_active Abandoned
- 1992-07-08 AU AU22721/92A patent/AU664191B2/en not_active Ceased
- 1992-07-08 FI FI931018A patent/FI931018L/fi unknown
- 1992-07-08 WO PCT/AT1992/000087 patent/WO1993000907A1/fr not_active Ceased

Also Published As

Publication number	Publication date
AU664191B2 (en)	1995-11-09
CA2091264A1 (fr)	1993-01-10
AT397102B (de)	1994-02-25
FI931018A0 (fi)	1993-03-08
FI931018A7 (fi)	1993-04-06
FI931018L (fi)	1993-04-06
ATA137591A (de)	1993-06-15
EP0548314A1 (fr)	1993-06-30
AU2272192A (en)	1993-02-11
WO1993000907A1 (fr)	1993-01-21

Publication	Publication Date	Title
EP1214945B1 (fr)	2005-06-08	Méthode et médicament destinés à inhiber l'expression d'un gène donné
DE69331946T2 (de)	2003-01-02	Nukleozyme
DE69125374T2 (de)	1997-10-23	Endonukleasen
CA2723672C (fr)	2019-09-03	Expression genique et douleur
JPS58501771A (ja)	1983-10-20	オリゴヌクレオチド治療剤及びその製法
US5484589A (en)	1996-01-16	Anti-viral methods using RNAse and DNAse
US9464292B2 (en)	2016-10-11	Sense oligonucleotide capable of controlling the expression of INOS and composition comprising the same
JP2018023367A (ja)	2018-02-15	転写因子デコイ
JPH04507083A (ja)	1992-12-10	規定された構造の短い治療用ｄｓＲＮＡ
AU2021374966B2 (en)	2025-10-09	Catalytic sequence based methods of treating or preventing bacterial infections
AU2002361482A1 (en)	2003-07-30	Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
JPH06503098A (ja)	1994-04-07	２−デオキシストレプトアミンのタイプの抗生物質の用途
DE69302369T2 (de)	1996-09-05	Erhöhung der katalytischen Aktivität von Ribozymen mit einem benachbartem Oligonukleotid als Heffer
Shahid	2007	Aminoglycosidic aminocyclitol antibiotics-A wonder, but toxic drugs: developments and clinical implications
CA3173776A1 (fr)	2021-09-02	Petits arn derives d'arn de transfert chimiquement modifies (arnts) pour cibler des bacteries pathogenes
EP1171629A1 (fr)	2002-01-16	Genes bacteriens essentiels et leurs proteines
WO2013042093A1 (fr)	2013-03-28	Utilisation de l'antibiotique bacitracine dans la dégradation hydrolytique d'arn
DD273445A1 (de)	1989-11-15	Verfahren zur herstellung von kovalenten konjugaten aus oligodesoxynukleotiden und polyaminosaeuren oder proteinen
DE102004002351A1 (de)	2005-08-11	Erfindung betreffend Wundheilung
JP2547714C (fr)	1999-07-12
HK1160487B (en)	2017-08-18	Oligoribonucucleotide for inhibiting the expression of a predefined gene